Iterative Design Trial to Assess Dietary Supplements and Other Aging-targeted Therapies

Part of paid clinical trials in New York, New York.

Sponsor
Atria Research and Global Health Institute (ARGHI)
Study ID
NCT07202403
Status
Enrolling By Invitation

Conditions

  • Aging
  • Longevity

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Accepted

Interventions

  • Spermidine — DIETARY_SUPPLEMENT
    Spermidine is a polyamine that forms naturally in plants, animals, and microorganisms as a byproduct of protein breakdown. While it's found in various foods, the highest concentrations are in wheat germ, soy, and fermented foods like cheese and miso (Madeo et al. 2018). Spermidine is known for its role in promoting autophagy, a cellular process that helps to clear damaged cells and improve overall cellular function (Eisenberg et al. 2009; Gabandé-Rodríguez, Gómez de Las Heras, and Mittelbrunn 2019). As a result, spermidine has recently attracted significant scientific interest for its potential to enhance lifespan and overall health in laboratory studies.

Study Details

This is a multi-cohort, open-label, adaptive trial designed to evaluate the safety, tolerability, and biological effects of dietary supplements and other aging-targeted therapies. Cohort 1 is a single-arm, open-label, intrapatient dose-escalation study evaluating the effects of escalating doses of spermidine in 10 participants. Patients will have baseline blood drawn and subsequently start daily administration of spermidine. They will receive capsules for three consecutive 28-day courses with escalating doses of 40mg, 120mg, and 400mg. Subsequent cohorts will evaluate additional agents.

Key Dates

Start date
Sep 30, 2025
Status verified
Sep 2025
Primary completion
Sep 30, 2030
Completion
Sep 30, 2031

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION

Arms

  • Experimental: Spermidine
    Participants will receive capsules for three consecutive 28-day courses with escalating doses of 40mg, 120mg, and 400mg.

Primary Outcome Measure

Safety and tolerability [ Time Frame: Baseline to Day 112 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Atria Research and Global Health InstituteNew YorkNew York10022-

Find similar trials in New York, NY

By research site
Atria Research and Global Health Institute· New York, NY

Related Studies